SCHEDULE: Bank of America Discloses 6.1% Stake in Ironwood Pharma
Beneficial Ownership Filing (Schedule 13G)
Bank of America Corporation has reported a beneficial ownership of 6.1% in Ironwood Pharmaceuticals Inc. as of March 31, 2026.
Summary
- Bank of America Corporation, through its subsidiaries, now holds a beneficial ownership of 9,962,355 shares of Ironwood Pharmaceuticals Inc. Class A Common Stock.
- This holding represents 6.1% of the class of securities.
- The filing is an amendment to a previous Schedule 13G filing.
- The beneficial ownership calculation is based on 163,058,316 outstanding shares as disclosed in Ironwood Pharmaceuticals' Form 10-K on February 26, 2026, with share totals as of January 31, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral; it is a routine disclosure of institutional ownership and does not inherently signal positive or negative performance for Ironwood Pharmaceuticals.
Positives
- Bank of America Corporation has disclosed a significant ownership stake, indicating potential institutional interest and confidence in Ironwood Pharmaceuticals.
Risks
- The filing does not explicitly mention any risks.
- Potential risks could include market volatility affecting the value of the investment, changes in Ironwood Pharmaceuticals' business performance, or regulatory changes impacting the pharmaceutical industry.
Future Outlook
The filing itself does not contain forward-looking statements or guidance from Ironwood Pharmaceuticals. It is a disclosure of ownership by Bank of America.
Industry Context
StockSavvy.ai notes that this Schedule 13G filing by Bank of America Corp /DE/ indicates a significant institutional holding in Ironwood Pharmaceuticals Inc. Such filings often signal sustained interest or a strategic investment by large financial institutions within the biotechnology and pharmaceutical sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor like Bank of America may be viewed positively by other shareholders, potentially indicating confidence in the company's future prospects.
- Management: The filing confirms a substantial ownership stake, which could influence board dynamics or strategic discussions.
- Creditors: No direct impact is indicated.
Next Steps
- Bank of America Corp /DE/ will continue to hold its shares in Ironwood Pharmaceuticals Inc.
- Ironwood Pharmaceuticals Inc. will continue its business operations and regulatory filings.
Key Dates
| Date | Description |
|---|---|
| 01/31/2026 | Date as of which share totals were reported in Ironwood Pharmaceuticals' Form 10-K. |
| 02/26/2026 | Date Ironwood Pharmaceuticals' Form 10-K was filed, disclosing outstanding share totals. |
| 03/31/2026 | Date of the event requiring the filing of this Schedule 13G statement. |
| 04/27/2026 | Date of signature for the Schedule 13G filing. |
Keywords
Schedule 13G, Bank of America, Ironwood Pharmaceuticals, Beneficial Ownership, Institutional Investor, Class A Common Stock, SEC Filing, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.